Pere Ginès Selected Research

Hyponatremia

11/2019	Improvement of hyponatremia in cirrhosis is associated with improved complex information processing.
5/2019	Serum sodium as a risk factor for hepatic encephalopathy in patients with cirrhosis and ascites.
1/2019	Hypervolemic Hyponatremia (Liver).
3/2017	Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience.
3/2012	Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
4/2011	Acute-on-chronic liver failure: the kidneys.
11/2010	Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension.
5/2010	[Hyponatremia in liver cirrhosis: pathogenesis and treatment].
6/2009	Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis.
5/2009	Portal hypertension.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pere Ginès Research Topics

Disease

97	Fibrosis (Cirrhosis) 11/2022 - 03/2002
32	Hepatorenal Syndrome 11/2021 - 03/2002
26	Ascites 01/2020 - 03/2002
20	Hyponatremia 11/2019 - 04/2003
17	Liver Diseases (Liver Disease) 01/2022 - 12/2006
16	Infections 10/2021 - 08/2006
15	Inflammation (Inflammations) 01/2022 - 07/2003
13	Alcoholic Hepatitis 01/2017 - 11/2003
12	Peritonitis 01/2021 - 08/2003
12	Renal Insufficiency (Renal Failure) 05/2017 - 09/2004
11	Hepatic Encephalopathy 11/2019 - 12/2002
10	End Stage Liver Disease 01/2022 - 06/2005
10	Liver Cirrhosis (Hepatic Cirrhosis) 10/2021 - 11/2006
10	Bacterial Infections (Bacterial Infection) 04/2021 - 10/2012
8	Necrosis 11/2021 - 08/2012
7	Portal Hypertension 10/2022 - 01/2005
7	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 09/2015
7	Acute-On-Chronic Liver Failure 04/2021 - 02/2007
5	Disease Progression 04/2021 - 09/2007
5	Chronic Renal Insufficiency 01/2020 - 08/2012
5	Hemorrhage 04/2012 - 12/2006
4	Hepatitis 01/2022 - 01/2016
4	Chronic Hepatitis C 06/2012 - 07/2007
3	Liver Failure 04/2021 - 01/2004
3	Hypovolemia 12/2018 - 05/2010
3	Cross Infection (Nosocomial Infection) 01/2016 - 05/2012
3	Septic Shock (Toxic Shock Syndrome) 04/2014 - 09/2004
3	Edema (Dropsy) 12/2012 - 01/2008
2	Hepatitis C 10/2022 - 07/2007
2	Non-alcoholic Fatty Liver Disease 10/2021 - 01/2018
2	Hepatitis B 10/2021 - 03/2012
2	Brain Diseases (Brain Disorder) 04/2021 - 12/2002
2	Fatty Liver 01/2021 - 01/2018
2	Rhabdomyolysis 01/2020 - 01/2019
2	Hepatocellular Carcinoma (Hepatoma) 01/2019 - 01/2018
2	Liver Neoplasms (Liver Cancer) 01/2019 - 01/2018
2	Sepsis (Septicemia) 05/2014 - 04/2004
2	Body Weight (Weight, Body) 07/2008 - 04/2003
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2022
1	Obesity 10/2021
1	Autoimmune Diseases (Autoimmune Disease) 10/2021

Drug/Important Bio-Agent (IBA)

29	SodiumIBA 01/2022 - 06/2004
22	AlbuminsIBA 01/2022 - 10/2002
20	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2011
15	Vasopressins (Vasopressin)IBA 11/2019 - 10/2002
15	CreatinineIBA 01/2019 - 08/2005
11	Vasoconstrictor AgentsIBA 11/2020 - 03/2002
11	TerlipressinIBA 01/2017 - 10/2002
8	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 11/2003
7	Lipocalin-2IBA 01/2022 - 08/2012
7	BilirubinIBA 12/2017 - 09/2007
7	Vasopressin Receptors (Arginine Vasopressin Receptor)IBA 05/2017 - 04/2003
6	DiureticsIBA 01/2016 - 03/2005
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2007
5	satavaptanIBA 11/2019 - 07/2008
5	ChemokinesIBA 01/2019 - 10/2014
5	CytokinesIBA 01/2019 - 10/2016
5	CollagenIBA 11/2016 - 07/2007
4	MicroRNAs (MicroRNA)IBA 04/2021 - 01/2016
4	Pharmaceutical PreparationsIBA 01/2021 - 03/2005
4	Tolvaptan FDA Link 01/2019 - 06/2007
4	Antidiuretic Hormone Receptor AntagonistsIBA 03/2012 - 04/2003
3	Rifaximin (L 105)FDA Link 01/2022 - 01/2020
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2020 - 02/2009
3	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2013 - 03/2002
3	Norfloxacin FDA Link 05/2012 - 09/2007
3	Inositol (Myoinositol)IBA 09/2010 - 06/2004
3	Angiotensin IIIBA 10/2009 - 07/2003
2	3,5- diethoxycarbonyl- 1,4- dihydrocollidineIBA 01/2022 - 01/2016
2	Fatty Acid-Binding ProteinsIBA 01/2022 - 12/2017
2	KynurenineIBA 01/2022 - 01/2019
2	Urea (Carbamide)FDA LinkGeneric 01/2022 - 09/2007
2	Tryptophan (L-Tryptophan)FDA Link 01/2022 - 01/2019
2	NitrogenIBA 01/2022 - 09/2007
2	Simvastatin (Zocor)FDA LinkGeneric 01/2022 - 01/2020
2	Midodrine (Midon)FDA LinkGeneric 01/2019 - 12/2018
2	InterleukinsIBA 07/2017 - 01/2017
2	SteroidsIBA 09/2015 - 11/2006
2	LipopolysaccharidesIBA 09/2015 - 11/2014
2	Carbon Tetrachloride (Tetrachloromethane)IBA 01/2015 - 03/2010
2	ReninIBA 01/2013 - 08/2005
2	ElectrolytesIBA 05/2010 - 06/2007
2	Losartan (Cozaar)FDA LinkGeneric 03/2010 - 10/2009
2	Transforming Growth Factor beta1 (TGF beta 1)IBA 02/2009 - 12/2007
2	Pentoxifylline (Trental)FDA LinkGeneric 06/2006 - 11/2003
1	Indicators and Reagents (Reagents)IBA 11/2022
1	RNA (Ribonucleic Acid)IBA 10/2022
1	LipidsIBA 01/2022
1	Carnitine (L-Carnitine)FDA LinkGeneric 01/2022
1	CopperIBA 10/2021
1	IronIBA 10/2021

Therapy/Procedure

32	Liver Transplantation 11/2021 - 01/2005
24	Therapeutics 01/2022 - 10/2002
7	Transplantation 11/2021 - 01/2004
2	Renal Replacement Therapy (Therapies, Renal Replacement) 01/2022 - 11/2015
2	Patient Readmission 01/2020 - 01/2016
2	Critical Care (Surgical Intensive Care) 11/2016 - 01/2012
2	Sodium-Restricted Diet (Diet, Sodium Restricted) 01/2016 - 02/2008
2	Surgical Portasystemic Shunt (Portosystemic Shunt) 09/2010 - 12/2002
2	Transjugular Intrahepatic Portasystemic Shunt 09/2010 - 12/2002